Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma

Cancer

Volumn 101, Issue 2, 2004, Pages 258-263

  Gonzalez Angulo, Ana M ^a   Krishnamurthy, Savitri ^a   Yamamura, Yuko ^a   Broglio, Kristine R ^a   Pusztai, Lajos ^a   Buzdar, Aman U ^a   Hortobagyi, Gabriel N ^a   Esteva, Francisco J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Her 2; Pathologic response; Preoperative chemotherapy; Taxanes

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PACLITAXEL; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; GENE AMPLIFICATION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE NEU; POLYMERASE CHAIN REACTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SURVIVAL RATE;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; MIDDLE AGED; PACLITAXEL; TAXOIDS; TREATMENT OUTCOME;

EID: 3042701052     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20348     Document Type: Article

References (24)

1. Esteva FJ, Hortobagyi GN. Locally advanced breast cancer. Hematol Oncol Clin North Am. 1999;13:457-472.
2. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460-469.
3. Esteva FJ. The current status of docetaxel for metastatic breast cancer. Oncology. 2002;16:17-26.
4. Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet. 1994;344:1267-1272.
5. Buzdar AU, Singletary SE, Theriault RL, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 1999;17:3412-3417.
6. Smith IC, Heys SD, Hutckeon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002;20:1456-1466.
7. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21:4165-4174.
8. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
9. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000;18:3651-3664.
10. Menard S, Valagussa P, Pilotti S, et al. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol. 2001;19:329-335.
11. Zhang F, Yang Y, Smith T, et al. Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer. 2003;97:1758-1765.
12. Thor AD, Berry DA, Budman DR, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst. 1998;90:1346-1360.
13. Seidman AD, Baselga J, Yao TJ, Gilewski T, Rosen PP, Norton L. HER-2/neu over-expression and clinical taxane sensitivity: a multivariate analysis in patients with metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol. 1996;15:A80.
14. Gianni L, Capri G, Mezzelani A, et al. HER-2/neu (HER2) amplification and response to doxorubicin/paclitaxel (AT) in women with metastatic breast cancer [abstract]. Proc Am Soc Clin Oncol. 1997;16:A491.
15. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
16. Van Poznak C, Tan L, Panageas KS, et al. Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. J Clin Oncol. 2002;20:2319-2326.
17. Hoang MP, Sahin AA, Ordonez NG, Sneige N. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol. 2000;113:852-859.
18. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:1800-1808.
19. Seidman AD, Fornier M, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 2001;19:2587-2595.
20. Nahta R, Esteva FJ. HER-2-targeted therapy: lessons learned and future directions. Clin Cancer Res. 2003;9:5078-5084.
21. Hamilton A, Larsimont D, Paridaens R, et al. A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923. Clin Breast Cancer. 2000;1:233-240.
22. Estevez LG, Cuevas JM, Anton A, et al. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study. Clin Cancer Res. 2003;9:686-692.
23. Burstein HJ, Harris LN, Gelman R, et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol. 2003;21:46-53.
24. Montgomery RB, Guzman J, O'Rourke DM, Stahl WL. Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression. J Biol Chem. 2000;275:17358-17363.